This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio
by Zacks Equity Research
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
Labcorp (LH) Presents New Research on Precision Diagnostics
by Zacks Equity Research
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
Charles River (CRL) Extends Gene Therapy Offering With New Pact
by Zacks Equity Research
Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
Intuitive Surgical's (ISRG) Da Vinci 5 Receives FDA Approval
by Zacks Equity Research
Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.
BD's (BDX) ADC System Favored by New Study for Long-Term Care
by Zacks Equity Research
BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
Inari Medical's (NARI) ClotTriever Improves Patient Outcome
by Zacks Equity Research
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?
by Zacks Equity Research
Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.
Zacks Industry Outlook Highlights Elevance Health, Cencora and ICON
by Zacks Equity Research
Elevance Health, Cencora and ICON are part of the Zacks Industry Outlook article.
UnitedHealth's (UNH) Payment System Disrupted by Cyberattack
by Zacks Equity Research
A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex
by Zacks Equity Research
AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.
Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable
by Zacks Equity Research
Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.
3 Medical Services Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most. However, staffing shortages continue to disrupt the growth trend.
Philips (PHG), AWS Unite to Scale Digital Pathology Solutions
by Zacks Equity Research
Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
by Zacks Equity Research
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
Why Cencora (COR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Integra LifeSciences (IART) Introduces MicroMatrix Flex
by Zacks Equity Research
Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
ClearPoint's (CLPT) Prism System Favored by Latest Study
by Zacks Equity Research
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
Here's Why You Should Retain BD (BDX) to Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.